AstraZeneca says booster jab effective against Omicron

Published December 24, 2021
People pose with a needle in front of displayed AstraZeneca logo in this illustration taken December 11. — Reuters
People pose with a needle in front of displayed AstraZeneca logo in this illustration taken December 11. — Reuters

LONDON: British pharmaceutical giant AstraZeneca said on Thursday that a third, or “booster”, dose of its Covid-19 vaccine Vaxzevria “significantly” lifted antibody levels against the Omicron strain in a laboratory study.

AstraZeneca also revealed in other findings that its preventative moniclonal antibody treatment, Evusheld, “retains neutralisation activity” against Omicron.

The threat of the highly transmissible Omicron variant looms large over the festive holidays, forcing many governments to roll out new curbs and urge citizens to get vaccinated. However, separate UK research on Thursday suggested that Omicron infections are less likely to result in hospitalisation compared to the Delta variant.

“Vaxzevria significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a third dose booster,” AstraZeneca said in a statement.

“The third dose booster vaccination neutralised the Omicron variant to levels that were broadly similar to those observed... after the second dose against the Delta variant.” Levels of neutralising antibodies were also higher with the booster jab than with individuals who had previously been infected and recovered naturally.

The study was conducted by investigators from the University of Oxford, which is the academic institution which helped AstraZeneca develop the vaccine last year.

Researchers analysed blood samples taken from individuals infected with Covid-19; those vaccinated with two doses plus a booster; and those who had reported previous infection. “It is very encouraging to see that current vaccines have the potential to protect against Omicron following a third dose booster,” said University of Oxford professor John Bell, one of the study investigators.

Published in Dawn, December 24th, 2021

Opinion

Editorial

Disregarding CCI
Updated 04 Nov, 2024

Disregarding CCI

The failure to regularly convene CCI meetings means that the process of democratic decision-making is falling apart.
Defeating TB
04 Nov, 2024

Defeating TB

CONSIDERING the fact that Pakistan has the fifth highest burden of tuberculosis in the world as per the World Health...
Ceasefire charade
Updated 04 Nov, 2024

Ceasefire charade

The US talks of peace, while simultaneously arming and funding their Israeli allies, are doomed to fail, and are little more than a charade.
Concerning measures
Updated 03 Nov, 2024

Concerning measures

The govt must seek political input and consensus on the changes it is seeking to make and be open about its intentions.
Short-lived relief?
03 Nov, 2024

Short-lived relief?

POLICYMAKERS must be jumping with joy. At the close of the first quarter of FY25, the budget posted a consolidated...
Brisk spread
03 Nov, 2024

Brisk spread

THE surge in polio cases has reached distressing levels with a tally of 45 last reported, after two cases emerged in...